The primary outcome will be the proportion of patients responding to treatment , defined in the depression trial as a PHQ-9 score < 10 and an absolute reduction in PHQ-9 5 after 4 months , and in the CVD risk trial as maintenance or reduction of 10-year CVD risk after 12 months .